about
Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor.EGFR kinase domain mutation positive lung cancers are sensitive to intrapleural perfusion with hyperthermic chemotherapy (IPHC) complete treatment.Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer.Mup-knockout mice generated through CRISPR/Cas9-mediated deletion for use in urinary protein analysisThe impact of the MYB-NFIB fusion proto-oncogene in vivo.Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerizationA DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo.An EGFR/PI3K/AKT axis promotes accumulation of the Rac1-GEF Tiam1 that is critical in EGFR-driven tumorigenesis.Discovery of Novel Inhibitor for WNT/β-Catenin Pathway by Tankyrase 1/2 Structure-Based Virtual ScreeningA tumor suppressor enhancing module orchestrated by GATA4 denotes a therapeutic opportunity for GATA4 deficient HCC patientsBlocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors
P50
Q36544650-2BE64608-2BB5-4999-B840-B78DB613983DQ36772144-E03A8885-B489-4449-944F-D468DA6AEF16Q36782296-89581B19-DB5C-460E-9DA2-C3F2242FA457Q36954821-F110EB8B-ED79-4A3E-AA0B-3758F88AC18EQ37362488-B520F234-6B38-447B-B114-1776895263D1Q41894424-F7A841C1-0182-4BA6-9963-DBDF42E2F69CQ50066041-18934A0A-4A6E-4A01-8CF8-081F881B4155Q53222808-09800587-5CB0-49BA-B77D-58B56C1E5C1AQ91733760-736F515C-3097-402D-8321-6F8D08E96AE3Q92424046-FE8BB9D5-6225-43F2-AFFC-547D0EE37A6BQ94549004-0D3EB6AE-BEBA-4F9D-9A4F-A144416C9C2C
P50
description
researcher (ORCID 0000-0001-7300-6604)
@en
name
Liang Chen
@en
type
label
Liang Chen
@en
prefLabel
Liang Chen
@en
P31
P496
0000-0001-7300-6604